View Filing Data

Print Document View Excel Document

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2015 shares
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Entity Registrant Name	EDAP TMS SA
Entity Central Index Key	0001041934
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	24,958,174
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	H1

Statement of Financial Position - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	€ 10,851	€ 11,142
Current portion of net trade accounts and notes receivable	9,121	6,943
Other receivables	1,037	1,200
Inventories	6,023	5,908
Deferred tax assets	33	40
Other assets, current portion	377	381
Short-term investment	1,000	1,000
Total current assets	28,442	26,615
Noncurrent Assets
Property and equipment, net	2,116	2,122
Intangible assets, net	24	24
Goodwill	2,412	2,412
Deposits and other non-current assets	354	344
Net trade accounts and notes receivable, non-current	553	638
Total assets	33,901	32,154
Current liabilities
Trade accounts and notes payable	4,977	5,505
Deferred revenues, current portion	1,928	1,102
Social security and other payroll withholdings taxes	834	872
Employee absences compensation	607	544
Income taxes payable	2	4
Other accrued liabilities	2,214	1,671
Short-term borrowings	2,982	2,126
Current portion of capital lease obligations	213	217
Current portion of long-term debt	117	116
Financial instruments carried at fair value, current	67	0
Total current liabilities	13,942	12,158
Deferred revenues, non-current	224	74
Capital lease obligations, non-current	287	355
Financial instruments carried at fair value, non current	3,523	2,092
Long-term debt, non-current	287	342
Other long-term liabilities	2,254	1,991
Total liabilities	20,518	17,013
Shareholders' equity
Common stock, €0.13 par value; 25,339,702 shares issued and 24,958,174 shares outstanding; 25,171,198 shares issued and 24,789,670 shares outstanding; at June 30, 2015 and at December 31, 2014, respectively	3,294	3,282
Additional paid-in capital	57,567	57,344
Retained earnings	(43,055)	(41,102)
Cumulative other comprehensive loss	(3,252)	(3,211)
Treasury stock, at cost; 381,528 at December 31, 2012 and 2011, respectively	(1,172)	(1,172)
Total shareholders' equity	13,383	15,141
Total liabilities and shareholders' equity	€ 33,901	€ 32,154

Statement of Financial Position (Parenthetical) - € / shares	Jun. 30, 2015	Jun. 30, 2014
Common Stock, Par Value Per Share	€ 0.13	€ 0.13
Common Stock, Shares, Issued	25,339,702	25,171,198
Common Stock, Shares, Outstanding	24,958,174	24,789,670
Treasury Stock, Shares	381,528	381,528

Statement of Operations - EUR (€) € in Thousands	6 Months Ended
Statement of Operations - EUR (€) € in Thousands	Jun. 30, 2015	Jun. 30, 2014
Revenues
Sales of goods	€ 9,103	€ 8,756
Sales of RPPs and leases	2,119	2,023
Sales of spare parts and services	2,830	2,618
Total sales	14,052	13,397
Total net sales		13,397
Other revenues	2	0
Total revenues	14,054	13,397
Cost of goods	(5,042)	(5,159)
Cost of RPPs & leases	(1,292)	(1,141)
Cost of spare parts and services	(1,809)	(1,730)
Total cost of sales	(8,143)	(8,030)
Gross profit	5,911	5,367
Operating Expenses
Research and development expenses	(1,512)	(1,618)
Selling and marketing expenses	(3,408)	(3,064)
General and administrative expenses	(1,830)	(1,732)
Loss from operations	(839)	(1,046)
Nonoperating Income (Expense)
Foreign currency exchange gain (loss), net	303	216
Other income (expense), net	(3)	(4)
Financial (expense) income, net	(1,344)	(3,554)
Income (loss) before taxes	(1,884)	(4,389)
Income tax (expense) benefit	(69)	(36)
Net income (loss)	€ (1,953)	€ (4,425)
Earnings per share
Basic net earnings (loss) per share	€ (0.08)	€ (0.20)
Diluted net earnings (loss) per share (1)	€ (0.08)	€ (0.20)
Shares outstanding	24,926,627	22,273,003
Diluted shares outstanding (1)	24,926,627	22,273,003

Statement of Cash Flows - EUR (€) € in Thousands	6 Months Ended
Statement of Cash Flows - EUR (€) € in Thousands	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net income (loss)	€ (1,953)	€ (4,425)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	356	467
Change in fair value	1,319	3,534
Other Non-cash compensation	27	105
Change in allowances for doubtful accounts & slow-moving inventories	105	(100)
Change in long-term provisions	12	86
Net capital loss on disposals of assets	39	10
Deferred tax expense/(benefit) (6)	22	(9)
Operating cash flow	(71)	(330)
Increase/Decrease in operating assets and liabilities:
Decrease/(Increase) in trade accounts and notes and other receivables	(818)	982
Decrease/(Increase) in inventories	(134)	(469)
Decrease/(Increase) in other assets	8	(168)
(Decrease)/Increase in trade accounts and notes payable	(587)	(905)
(Decrease)/Increase in accrued expenses, other current liabilities	766	433
Net increase (decrease) in operating assets and liabilities	(764)	(126)
Net cash used in operating activities	(836)	(456)
Cash flows from investing activities:
Additions to capitalized assets produced by the Company	(101)	(393)
Net proceeds from sale of leased back assets	0	0
Acquisitions of property and equipment	(207)	(76)
Acquisitions of intangible assets	(1)	(4)
Acquisitions of short term investments	0	(4,994)
Net proceeds from sale of assets	0	0
Increase (decrease) in deposits and guarantees, net	4	(16)
Net cash used in investing activities	(306)	(5,483)
Cash flow from financing activities:
Proceeds from capital increase	208	6,383
Proceeds from long term borrowings, net of financing costs	0	242
Repayment of long term borrowings	(69)	(57)
Repayment of obligations under capital leases	(120)	(112)
Increase/(decrease) in bank overdrafts and short-term borrowings	856	(233)
Net cash used in financing activities	875	6,222
Net effect of exchange rate changes on cash and cash equivalents	(25)	(161)
Net decrease in cash and cash equivalents	(292)	123
Cash and cash equivalents at beginning of year	11,142	6,681
Cash and cash equivalents at end of period	€ 10,851	€ 6,804

Statement of Stockholders Equity - 6 months ended Jun. 30, 2015 - EUR (€) € in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total
Beginning Balance at Dec. 31, 2014	€ 3,282	€ 57,344	€ (3,211)	€ (41,102)	€ (1,172)	€ 15,141
Net income (loss)				(1,953)		(1,953)
Translation adjustment			(41)			(41)
Warrants and stock options granted		27				27
Capital increase	€ 12	196				208
Capital increase (Shares)	92,754
Ending Balance at Jun. 30, 2015	€ 3,294	€ 57,567	€ (3,252)	€ (43,055)	€ (1,172)	€ 13,383
Ending Balance (Shares) at Jun. 30, 2015	24,958,174

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Statement of Comprehensive Income - EUR (€) € in Thousands	6 Months Ended
Statement of Comprehensive Income - EUR (€) € in Thousands	Jun. 30, 2015	Jun. 30, 2014
Net income (loss)	€ (1,953)	€ (4,425)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Summary Of Significant Accounting Policies

6 Months Ended

Jun. 30, 2015

Summary Of Significant Accounting Policies [Text Block]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1 - 1

Nature of operations

EDAP TMS S.A. and its subsidiaries (‘‘the Company’’) are engaged in the development, production, marketing, distribution and maintenance of a portfolio of minimally-invasive medical devices for the treatment of urological diseases. The Company currently produces devices for treating stones of the urinary tract and localized prostate cancer. Net sales consist primarily of direct sales to hospitals and clinics in France and Europe, export sales to third-party distributors and agents, and export sales through subsidiaries based in Germany, Italy, Asia and the United States.

The Company purchases the majority of the components used in its products from a number of suppliers but for some components, relies on a single source. Delay would be caused if the supply of these components or other components was interrupted and these delays could be extended in certain situations where a component substitution may require regulatory approval. Failure to obtain adequate supplies of these components in a timely manner could have a material adverse effect on the Company’s business, financial position and results of operation.

1 - 2

Management estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (‘‘U.S. GAAP’’) requires management to make estimates and assumptions, such as business plans, stock price volatility, duration of standard warranty per market and cost of maintenance contract used to determine the amount of revenue to differ. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

1 - 3

Consolidation

The accompanying consolidated financial statements include the accounts of EDAP TMS S.A. and all its domestic and foreign owned subsidiaries, which include EDAP TMS France SAS, EDAP Technomed Inc. (USA), Edap Technomed Sdn Bhd (Malaysia), Edap Technomed Italia S.R.L, EDAP Technomed Co. Ltd. (Japan) and EDAP TMS Gmbh (Germany). Edap Technomed Sdn Bhd was incorporated in early 1997. Edap Technomed Co. Ltd. was created in late 1996. EDAP TMS Gmbh was created in July 2006. EDAP SA, a subsidiary incorporating HIFU activities merged all of its activity into EDAP TMS France SAS in 2008. All intercompany transactions and balances are eliminated in consolidation.

1 - 4

Revenue recognition

Sales of goods:

For medical device sales with no significant remaining vendor obligation, payments contingent upon customer financing, acceptance criteria that can be subjectively interpreted by the customer, or tied to the use of the device, revenue is recognized when evidence of an arrangement exists, title to the device passes (depending on terms, either upon shipment or delivery), and the customer has the intent and ability to pay in accordance with contract payment terms that are fixed or determinable. For sales in which payment is contingent upon customer financing, acceptance criteria can be subjectively interpreted by the customer, or payment depends on use of the device, revenue is recognized when the contingency is resolved. The Company provides training and provides a minimum of one-year warranty upon installation. The Company accrues for the estimated training and warranty costs at the time of sale. Revenues related to disposables are recognized when goods are delivered.

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data)

Sales of RPPs and leases:

Revenues related to the sale of HIFU treatments invoiced on a ‘‘Revenue-Per-Procedure’’ (‘‘RPP’’) basis are recognized when the treatment procedure has been completed. Revenues from devices leased to customers under operating leases are recognized on a straight-line basis.

Sales of spare parts and services:

Revenues related to spare parts are recognized when goods are delivered. Maintenance contracts rarely exceed one year and are recognized on a linear basis. Billings or cash receipts in advance of services due under maintenance contracts are recorded as deferred revenue.

1 - 5

Shipping and handling costs

The Company recognizes revenue from the shipping and handling of its products as a component of revenue. Shipping and handling costs are recorded as a component of cost of sales.

1 - 6

Cash equivalents and short term investments

Cash equivalents are cash investments which are highly liquid and have initial maturities of 90 days or less.

Cash investments with a maturity higher than 90 days are considered as short-term investments.

1 - 7

Accounts Receivables

Accounts receivables are stated at cost net of allowances for doubtful accounts. The Company makes judgments as to its ability to collect outstanding receivables and provides allowances for the portion of receivables when collection becomes doubtful. Provision is made based upon a specific review of all significant outstanding invoices. These estimates are based on our bad debt write-off experience, analysis of credit information, specific identification of probable bad debt based on our collection efforts, aging of accounts receivables and other known factors.

1 - 8

Inventories

Inventories are valued at the lower of manufacturing cost, which is principally comprised of components and labor costs, or market (net realizable value). Cost is determined on a first-in, first-out basis for components and spare parts and by specific identification for finished goods (medical devices). The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow moving, first based on a detailed comparison between quantity in inventory and historical consumption and then based on case-by-case analysis of the difference between the cost of inventory and the related estimated market value.

1 - 9 Property and equipment

Property and equipment is stated at historical cost. Depreciation and amortization of property and equipment are calculated using the straight-line method over the estimated useful life of the related assets, as follows:

Leasehold improvements	10 years or lease term if shorter
Equipment	3 - 10 years
Furniture, fixtures, fittings and other	2 - 10 years

Equipment includes industrial equipment and research equipment that has alternative future uses. Equipment also includes devices that are manufactured by the Company and leased to customers through operating leases related to Revenue-Per-Procedure transactions and devices subject to sale and leaseback transactions. This equipment is depreciated over a period of seven years.

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data)

1 - 10

Long-lived assets

The Company reviews the carrying value of its long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable. Recoverability of long-lived assets is assessed by a comparison of the carrying amount of the assets (or the Group of assets, including the asset in question, that represents the lowest level of separately-identifiable cash flows) to the total estimated undiscounted cash flows expected to be generated by the asset or group of assets. If the future net undiscounted cash flows is less than the carrying amount of the asset or group of assets, the asset or group of assets is considered impaired and an expense is recognized equal to the amount required to reduce the carrying amount of the asset or group of assets to its then fair value. Fair value is determined by discounting the cash flows expected to be generated by the assets, when the quoted market prices are not available for the long-lived assets. Estimated future cash flows are based on assumptions and are subject to risk and uncertainty.

1 - 11 Goodwill and intangible assets

Goodwill represents the excess of purchase price over the fair value of identifiable net assets of businesses acquired. Goodwill is not amortized but instead tested annually for impairment or more frequently when events or change in circumstances indicate that the assets might be impaired by comparing the carrying value to the fair value of the reporting units to which it is assigned. Under ASC 350, “Goodwill and other intangible assets”, the impairment test is performed in two steps. The first step compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit is less than its carrying amount, a second step is performed to measure the amount of impairment loss. The second step allocates the fair value of the reporting unit to the Company’s tangible and intangible assets and liabilities. This derives an implied fair value for the reporting unit’s goodwill. If the carrying amount of the reporting units goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized equal to that excess. For the purpose of any impairment test, the Company relies upon projections of future undiscounted cash flows and takes into account assumptions regarding the evolution of the market and its ability to successfully develop and commercialize its products.

Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses.

Intangible assets consist primarily of purchased patents relating to lithotripters, purchased licenses, a purchased trade name and a purchased trademark. The basis for valuation of these assets is their historical acquisition cost. Amortization of intangible assets is calculated by the straight-line method over the shorter of the contractual or estimated useful life of the assets, as follows:

Patents	5 years
Licenses	5 years
Trade name and trademark	7 years

1 - 12

Treasury Stocks

Treasury stock purchases are accounted for at cost. The sale of treasury stocks is accounted for using the first in first out method. Gains on the sale or retirement of treasury stocks are accounted for as additional paid-in capital whereas losses on the sale or retirement of treasury stock are recorded as additional paid-in capital to the extent that previous net gains from sale or retirement of treasury stocks are included therein; otherwise the losses shall be recorded to accumulated benefit (deficit) account. Gains or losses from the sale or retirement of treasury stock do not affect reported results of operations.

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data)

1 - 13

Warranty expenses

The Company provides customers with a warranty for each product sold and accrues warranty expense at time of sale based upon historical claims experience. Standard warranty period may vary from 1 year to 2 years depending on the market. Actual warranty costs incurred are charged against the accrual when paid and are classified in cost of sales in the statement of income.

1 - 14

Income taxes

The Company accounts for income taxes in accordance with ASC 740, ‘‘Accounting for Income Taxes’’ Under ASC 740, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured by applying enacted tax rates and laws to taxable years in which such differences are expected to reverse. A valuation allowance is established if, based on the weight of available evidence, it is more likely than not that some portion, or all of the deferred tax assets, will not be realized. In accordance with ASC740, no provision has been made for income or withholding taxes on undistributed earnings of foreign subsidiaries, such undistributed earnings being permanently reinvested.

As of January 1, 2007, the Company adopted FIN48 (now ASC 740) "Accounting for uncertainty in income tax". Under ASC740, the measurement of a tax position that meets the more-likely-that-not recognition threshold must take into consideration the amounts and probabilities of the outcomes that could be realized upon ultimate settlement using the facts, circumstances and information available at the reporting date.

1 - 15

Research and development costs

Research and development costs are recorded as an expense in the period in which they are incurred. The French government provides tax credits to companies for innovative research and development. This tax credit is calculated based on a percentage of eligible research and development costs and it can be refundable in cash and is not contingent on future taxable income. As such, the Company considers the research tax credits as a grant, offsetting operating expenses.

1 - 16

Advertising costs

Advertising costs are recorded as an expense in the period in which they are incurred.

1 - 17

Foreign currency translation and transactions

Translation of the financial statements of consolidated companies

The reporting currency of EDAP TMS S.A. for all years presented is the euro (€). The functional currency of each subsidiary is its local currency. In accordance with ASC 830, all accounts in the financial statements are translated into euro from the functional currency at exchange rate as follows:

•	assets and liabilities are translated at year-end exchange rates;
•	shareholders’ equity is translated at historical exchange rates (as of the date of contribution);
•	statement of income items are translated at average exchange rates for the year; and
•	translation gains and losses are recorded in a separate component of shareholders’ equity.

Foreign currencies transactions

Transactions involving foreign currencies are translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables denominated in foreign currencies are translated at year-end exchange rates. The resulting unrealized exchange gains and losses are carried to the statement of income.

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data)

1 - 18

Earnings per share

Basic earnings per share are computed by dividing income available to common shareholders by the number of shares of common stock outstanding for the period. Diluted earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted from U.S. dollars at the average exchange rate for the period.

1 - 19

Derivative instruments

ASC 815 requires the Company to recognize all of its derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must classify the hedging instrument, based upon the exposure being hedged, as fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.

Gains and losses from derivative instruments are recorded in the income statement.

1 - 20

Employee stock option plans

At June 30, 2015, the Company had three stock-based employee compensation plans. The Company adopted ASC 718, “Share-Based Payment”, effective January 1, 2006. ASC 718 requires the recognition of fair value of stock compensation as an expense in the calculation of net income (loss).

The fair value of each stock option granted over the period is estimated on the date of grant using the Black-Scholes option pricing model. The Company did not make any stock option grant during the year ended December 31, 2014 nor during the 6 -month period ended June 30, 2015.

1 - 21

Warrants

On March 28, 2012, pursuant to a securities purchase agreement dated March 22, 2012, as amended, the Company issued new ordinary shares in the form of ADSs to selected institutional investors in a registered direct placement (the “March 2012 Placement”) with warrants attached (the “March 2012 Investor Warrants”). The Company also issued warrants to the placement agent, Rodman & Renshaw LLC (the “March 2012 Placement Agent Warrants” and together with the March 2012 Investor Warrants, the “March 2012 Warrants”). The Company has accounted for the March 2012 Warrants as a liability and reflected this analysis in the Company’s financial statements filed for the year 2012.

The Company used the Black-Scholes pricing model to value the March 2012 Warrants at inception, with changes in fair value recorded as a financial expense or income.

On May 28, 2013, pursuant to a securities purchase agreement dated May 20, 2013, as amended, the Company issued new ordinary shares in the form of ADSs to selected institutional investors in a registered direct placement (the “May 2013 Placement”) with warrants attached (the “May 2013 Investor Warrants”). The Company also issued warrants to the placement agent, H.C. Wainwright & Co., LLC (the “May 2013 Placement Agent Warrants” and together with the May 2013 Investor Warrants, the “May 2013 Warrants”). As the May 2013 Warrants comprised the same structure and provisions than the March 2012 Warrants, including an exercise price determined in U.S. dollars while the functional currency of the Company is the Euro, the Company determined that the May 2013 Warrants should be accounted for as a liability.

The Company used the Black-Scholes pricing model to value the May 2013 Warrants at inception, with changes in fair value recorded as a financial expense or income.

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data

1 - 22

Leases and Sales and leaseback transactions

In accordance with ASC 840, Accounting for Leases, the Company classifies all leases at the inception date as either a capital lease or an operating lease. A lease is a capital lease if it meets any one of the following criteria; otherwise, it is an operating lease:

-	Ownership is transferred to the lessee by the end of the lease term;
-	The lease contains a bargain purchase option;
-	The lease term is at least 75% of the property's estimated remaining economic life;
-	The present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date.

The Company enters into sale and leaseback transactions from time to time. In accordance with ASC 840, any profit or loss on the sale is deferred and amortized prospectively over the term of the lease, in proportion to the leased asset if a capital lease, or in proportion to the related gross rental charged to expense over the lease term, if an operating lease.

Cash and Cash Equivalents Disclosure

6 Months Ended

Jun. 30, 2015

Cash and Cash Equivalents Disclosure [Text Block]

CASH, CASH EQUIVALENTS AND SHORT TERM INVESTMENTS

Cash and cash equivalents and short terms investments are comprised of the following:

	06 - 30 - 2015		12 - 31 - 2014
Total cash and cash equivalents		10,851		11,142
Short term investments		1,000		1,000
Total cash and cash equivalent and short term investments		11,851		12,142

Short term investments are comprised of money market funds. The aggregate fair value of the short term investments is consistent with their book value.

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References + Details

Inventories

6 Months Ended

Jun. 30, 2015

Inventories [Text Block]

NVENTORIES

Inventories consist of the following:

	06 - 30 - 2015			12 - 31 - 2014
Components, spare parts		3,812			4,225
Work-in-progress		1,056			832
Finished goods		2,029			1,591
Total gross inventories		6,898			6,648
Less: provision for slow-moving inventory		(874	)		(741	)
Total		6,023			5,908

Lease Obligations

6 Months Ended

Jun. 30, 2015

Lease Obligations [Text Block]

CAPITAL LEASE OBLIGATIONS

The Company leases certain of its equipment under capital leases. At June 30, 2015, this equipment consists mainly of medical devices for an amount of € 209 thousand and vehicles for an amount of € 291 thousand.

Long-Term Debt

6 Months Ended

Jun. 30, 2015

Long-Term Debt [Text Block]

LONG TERM DEBT, AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE

6 - 1 Long-term debt:

	06 - 30 - 2015			12 - 31 - 2014
Japanese yen term loan		203			234
Italy term loan		198			220
Malaysia term loan		3			5
Total long term debt		404			458
Less current portion		(117	)		(116	)
Total long-term portion		287			342

As of December 31, 2014, long-term debt in Japan consists of 3 loans in Yen with the following conditions:

	Amount		Maturation		Interest rate
EDAP Technomed Co. Ltd		10,000,000		March 31, 2015		0.10%
		55,000,000		June 30, 2018		1.80%
		10,000,000		June 30, 2018		0.10%

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data)

As of June 30, 2015, long-term debt in Japan consists of 2 loans in Yen with the following conditions:

	Amount		Maturation		Interest rate
EDAP Technomed Co. Ltd		55,000,000		June 30, 2018		1.80%
		10,000,000		June 30, 2018		0.10%

As of December 31, 2014, long-term debt in Italy consists of a loan in euros of an initial amount of € 242 thousand with an interest rate at Euribor 1 month + 4.5% due to mature on June 6, 2019.

As of June 30, 2015, long-term debt in Italy consists of a loan in euros amounting to € 242 thousand with an interest rate at Euribor 1 month + 4.5% due to mature on June 6, 2019.

6 - 2 Financial instruments carried at fair value:

	06 - 30 - 2015			12 - 31 - 2014

Investor Warrants		3,434			1,943
Placement Agent Warrants		155			148
Total		3,589			2,092
Less current portion		(67	)		-
Total long-term portion		3,523			2,092

On March 28, 2012, pursuant to a securities purchase agreement dated March 22, 2012, as amended, the Company issued 2,812,500 ordinary shares in the form of ADSs to selected institutional investors in a registered direct placement (the “March 2012 Placement”), at a price of $2.00 per share, with warrants attached (the “March 2012 Investor Warrants”). The March 2012 Investor Warrants allow investors to purchase up to 1,406,250 shares in the form of ADSs at an exercise price of $2.75. The March 2012 Investor Warrants are exercisable immediately and expire on March 28, 2017. The Company also issued warrants to purchase up to 168,750 shares in the form of ADSs to the placement agent, Rodman & Renshaw LLC, with an exercise price of $2.50 (the “March 2012 Placement Agent Warrants” and together with the Investor Warrants, the “March 2012 Warrants”). The March 2012 Placement Agent Warrants are exercisable from September 24, 2012 and expire on October 21, 2016. Total gross proceeds for the placement amounted to $5.625 million (€ 4.214 million) out of which $2.429 million (€ 1.821 million) allocated to the Investor and Placement Agent Warrants based on their fair value and accounted for as liability, and the remaining $3.196 million (€ 2.393 million) allocated to the share capital increase.

The form of the securities purchase agreement and the form of Investor Warrant were furnished to the SEC on our report on Form 6-K dated March 28, 2012.

The Company determined that the March 2012 Warrants to purchase up to 1,575,000 new ordinary shares of the Company ( 1,406,250 shares underlying the March 2012 Investor Warrants and 168,750 shares underlying the March 2012 Placement Agent Warrants) should be accounted for as a liability.

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data)

On May 28, 2013, pursuant to a securities purchase agreement dated May 20, 2013, as amended, the Company issued 3,000,000 ordinary shares in the form of ADSs to selected institutional investors in a registered direct placement (the “May 2013 Placement”), at a price of $4.00 per share, with warrants attached (the “May 2013 Investor Warrants”). The May 2013 Investor Warrants allow investors to purchase up to 1,500,000 shares in the form of ADSs at an exercise price of $4.25. The May 2013 Investor Warrants are exercisable from November 29, 2013 and expire on November 29, 2018. The Company also issued warrants to purchase up to 180,000 shares in the form of ADSs to the placement agent, H.C. Wainwright & Co., LLC, with an exercise price of $5.00 per share (the “May 2013 Placement Agent Warrants” and together with the Investor Warrants, the “May 2013 Warrants”). The May 2013 Placement Agent Warrants are exercisable from November 29, 2013 and expire on May 28, 2016. As the May 2013 Warrants comprised the same structure and provisions than the March 2012 Warrants, including an exercise price determined in U.S. dollars while the functional currency of the Company is the Euro, the Company determined that the May 2013 Warrants should be accounted for as a liability. Total gross proceeds for the placement amounted to $12.0 million (€ 9.270 million), out of which $3.817 million (€ 2.950 million) allocated to the Investor and Placement Agent Warrants based on their fair value and accounted for as liability, and the remaining $8.183 million (€ 6.320 million) allocated to the share capital increase. The form of the securities purchase agreement and the form of Investor Warrant were furnished to the SEC on our report on Form 6-K dated May 28, 2013.

The Company used the Black-Scholes pricing model to value the May 2013 Warrants at inception, with changes in fair value recorded as a financial expense or income.

Fair Value of the March 2012 Investor Warrants:

The valuation model of the Investor Warrants uses a Black-Scholes model.

At inception date, the Black-Scholes valuation model used the following main assumptions and parameters:

Share price at closing date: $1.95

Strike price of warrants: $2.75

Risk free interest rate at 5 years: 1.05%

Share price volatility: 120%

Dividend rates: 0%

As of December 31, 2014, the Black-Scholes valuation model used the following main assumptions and parameters:

Warrants’ maturity is assumed to be their legal duration as per Warrant contract

Share price at closing date: $2.33

Strike price of warrants: $2.75

Risk free interest rate at 5 years: 0.07%

Share price volatility: 70%

Dividend rates: 0%

As of June 30, 2015, the Black-Scholes valuation model used the following main assumptions and parameters:

Share price at closing date: $3.25

Strike price of warrants: $2.75

Risk free interest rate at 5 years: 0.55%

Share price volatility: 70%

Dividend rates: 0%

On that basis, the unit fair value of the Investor Warrants was $1.55 per warrant at inception date, $0.82 per warrant as of December 31, 2014, and $1.35 per warrant as of June 30, 2015. The total fair value for the issued Investor warrants was $2.173 million at inception date, $1,084 million as of December 31, 2014 and $1,781 million as of June 30, 2015.

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data)

Fair Value of the March 2012 Placement Agent Warrants:

The valuation model of the Placement Agent Warrants uses a Black-Scholes model.

At inception date, the Black-Scholes valuation model used the following main assumptions and parameters:

Share price at closing date: $1.95

Strike price of warrants: $2.5

Risk free interest rate at 4.5 years: 0.92%

Share price volatility: 120%

Dividend rates: 0%

As of December 31, 2014, the Black-Scholes valuation model used the following main assumptions and parameters:

Warrants’ maturity is assumed to be their legal duration as per Warrant contract

Share price at closing date: $2.33

Strike price of warrants: $2.5

Risk free interest rate at 4.5 years: 0.06%

Share price volatility: 70%

Dividend rates: 0%

As of June 30, 2015, the Black-Scholes valuation model used the following main assumptions and parameters:

Share price at closing date: $3.25

Strike price of warrants: $2.5

Risk free interest rate at 4.5 years: 0.37%

Share price volatility: 70%

Dividend rates: 0%

On that basis, the unit fair value of the Placement Agent Warrants was $1.52 per warrant at inception date, $0.79 per warrant as of December 31, 2014, and $1.30 per warrant as of June 30, 2015. The total fair value for the issued Placement Agent warrants was $0.256 million at inception date, $0.133 million as of December 31, 2014, and $0.099 million as of June 30, 2015.

Fair Value of the May 2013 Investor Warrants:

The valuation model of the Investor Warrants uses a Black-Scholes model.

At inception date, the Black-Scholes valuation model used the following main assumptions and parameters:

Share price at closing date: $3.96

Strike price of warrants: $4.25

Risk free interest rate at 5.5 years: 1.07%

Share price volatility: 71%

Dividend rates: 0%

As of June 30, 2015, the Black-Scholes valuation model used the following main assumptions and parameters:

Share price at closing date: $3.25

Strike price of warrants: $4.25

Risk free interest rate at 5.5 years: 1.14%

Share price volatility: 70%

Dividend rates: 0%

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data)

On that basis, the unit fair value of the Investor Warrants was $2.35 per warrant at inception date, $0.85 per warrant as of December 31, 2014 and $1.37 per warrant as of June 30, 2015. The total fair value for the issued Investor warrants was $3.525 million at inception date, $1.275 million as of December 31, 2014 and $2.062 million as of June 30, 2015.

Fair Value of the May 2013 Placement Agent Warrants:

The valuation model of the Placement Agent Warrants uses a Black-Scholes model.

At inception date, the Black-Scholes valuation model used the following main assumptions and parameters:

Share price at closing date: $3.96

Strike price of warrants: $5.00

Risk free interest rate at 3 years: 0.36%

Share price volatility: 72%

Dividend rates: 0%

As of December 31, 2014, the Black-Scholes valuation model used the following main assumptions and parameters:

Warrants’ maturity is assumed to be their legal duration as per Warrant contract

Share price at closing date: $2.33

Strike price of warrants: $5.00

Risk free interest rate at 3 years: 0.06%

Share price volatility: 70%

Dividend rates: 0%

As of June 30, 2015, the Black-Scholes valuation model used the following main assumptions and parameters:

Share price at closing date: $3.25

Strike price of warrants: $5.00

Risk free interest rate at 3 years: 0.25%

Share price volatility: 70%

Dividend rates: 0%

On that basis, the unit fair value of the Placement Agent Warrants was $1.62 per warrant at inception date, $0.26 per warrant as of December 31, 2014 and $0.41 per warrant as of June 30, 2015. The total fair value for the issued Placement Agent warrants was $0.292 million at inception date, $0.047 million as of December 31, 2014 and $0.074 million as of June 30, 2015.

Long-term debt and financial instruments carried at fair value at June 30, 2015 mature as follows:

2015			52
2016			272
2017			1,709
2018			1,934
2019			27
Total			3,994

Short-Term Borrowings

6 Months Ended

Jun. 30, 2015

Short-Term Borrowings [Text Block]

SHORT-TERM BORROWINGS

As of June 30, 2015, short-term borrowings consist mainly of € 1,980 thousand of account receivables factored and for which the Company is supporting the risk of non-collection and loans in euros amounting to € 1,000 thousand with the following conditions:

‘000 Euros

Amount

Maturation

Interest rate

EDAP-TMS France SAS

1,000

November 19, 2015

Euribor + 0,7%

As of June 30, 2014, short-term borrowings consist mainly of € 972 thousand of account receivables factored and for which the Company is supporting the risk of non-collection and loans in euros amounting to € 1,000 thousand with the following conditions:

‘000 Euros

Amount

Maturation

Interest rate

EDAP-TMS France SAS

1,000

October 21, 2014

Euribor + 0,5%

Shareholders Equity

6 Months Ended

Jun. 30, 2015

Shareholders Equity [Text Block]

7 —SHAREHOLDERS’ EQUITY

7 - 1 Common stock

As of June 30, 2015, EDAP TMS S.A.’s common stock consisted of 25,339,702 issued shares, fully paid, and with a par value of € 0.13 each. 24,958,174 of the shares were outstanding.

7 - 2 Pre-emptive subscription rights

Shareholders have preemptive rights to subscribe on a pro rata basis for additional shares issued by the Company for cash. Shareholders may waive such preemptive subscription rights at an extraordinary general meeting of shareholders under certain circumstances. Preemptive subscription rights, if not previously waived, are transferable during the subscription period relating to a particular offer of shares.

7 - 3 Dividend rights

Dividends may be distributed from the statutory retained earnings, subject to the requirements of French law and the Company’s by-laws. The Company has not distributed any dividends since its inception.

7 - 4 Treasury stock

As of June 30, 2015, the 381,528 shares of treasury stock consisted of (i) 331,988 shares acquired between August and December 1998 for € 956 thousand and (ii) 49,540 shares acquired in June and July 2001 for € 150 thousand. All 381,528 shares of treasury stock have been acquired to cover outstanding stock options (see Note 7-5).

7 - 5 Stock-option plans

As of June 30, 2015, the 381,528 ordinary shares held as treasury stock were dedicated to serve stock purchase option plans as follows: 174,100 shares which may be purchased at a price of € 2.38 per share pursuant to the exercise of options that were granted on June 25, 2010.

As of June 30 2015, the Company sponsored three stock purchase and subscription option plans:

On May 22, 2007, the shareholders of the Company authorized the Board of Directors to grant up to 600,000 options to subscribe to 600,000 new Shares. Conforming to this stock option plan, the Board of Directors granted 504,088 options to subscribe to new Shares to certain employees of EDAP TMS on October 29, 2007, and 95,912 options to subscribe to new Shares to certain employees of EDAP TMS on June 25, 2010. Under this plan, a total of 440,500 options to subscribe to new shares were still in force on June 30, 2015.

On June 24, 2010, the shareholders of the Company authorized the Board of Directors to grant up to 229,100 options to purchase up to 229,100 Shares. Conforming to this stock option plan, the Board of Directors granted 229,100 options to purchase Shares to certain employees of EDAP TMS on June 25, 2010. Under this plan, 149,100 options were still in force on June 30, 2015.

On December 19, 2012, the shareholders authorized the Board of Directors to grant up to 500,000 options to subscribe to 500,000 new shares at a fixed price to be set by the Board of Directors. Conforming to this stock option plan, the Board of Directors granted 500,000 options to subscribe Shares to certain employees of EDAP TMS on January 18, 2013. Under this plan, 400,000 options were still in force on June 30, 2015.

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data)

As of June 30, 2015, a summary of stock option activity to purchase or to subscribe to Shares under these plans is as follows:

	June 30, 2015					December 31, 2014					December 31, 2013
	Options			Weighted average exercise price (€)		Options			Weighted average exercise price (€)		Options		Weighted average exercise price (€)
Outstanding on January 1,		1,095,850			2.76		1,310,850			2.70		810,850		3.18
Granted		-			-		-			-		500,000		1.91
Exercised		-			-		(750	)		3.99		-		-
Forfeited		(106,250	)		2.88		(90,250	)		2.07		-		-
Expired		-			-		(124,000	)		2.60		-		-
Outstanding at the end of the period		989,600			2.74		1,095,850			2.76		1,310,850		2.70
Exercisable at the end of the period		797,100			2.95		784,600			3.09		743,347		3.27
Shares purchase options available for grant on at end of period		232,428					83,428					83,428

The following table summarizes information about options to purchase Shares already held by the Company as treasury Shares, or to subscribe to new Shares, at June 30, 2015:

	Outstanding options								Fully vested options ⁽¹⁾
Exercise price (€)	Options		Weighted average remaining contractual life		Weighted average exercise price (€)		Aggregate Intrinsic Value ⁽²⁾		Options		Weighted average exercise price (€)		Aggregate Intrinsic Value ⁽²⁾
3.99		364,588		2.3		3.99		-		364,588		3.99		-
2.38		149,100		5.0		2.38		78,224		149,100		2.38		78,224
1.91		400,000		7.5		1.91		397,855		207,500		1.91		206,387
1.88		75,912		5.5		1.88		77,782		75,912		1.88		77,782
1.88 to 3.99		989,600		5.0		2.74		553,861		797,100		2.95		362,393

(1)	Fully vested options are all exercisable options
(2)	The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $3.25 at June 30, 2015, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.

The Company applies FAS 123R on Share Based Payments and its related interpretations in accounting for its employee stock options.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Financial Income, Net

6 Months Ended

Jun. 30, 2015

Financial Income, Net [Text Block]

FINANCIAL INCOME, NET

Interest (expense) income, net consists of the following:

	6 months 2015			6 months 2014
Interest income 12		3			12
Interest expense		(28	)		(32	)
Warrants exercises		66			-
Changes in fair value of the warrants		(1,385	)		(3,534	)
Total		(1,344	)		(3,554	)

Segment Information

6 Months Ended

Jun. 30, 2015

Segment Information [Text Block]

SEGMENT INFORMATION

In July of fiscal year 2002, the Company announced an organizational realignment that created two operating divisions within the Company. For reporting purposes, this organizational realignment created three reporting segments: the holding company, EDAP TMS S.A. (‘EDAP TMS Corporate’), the High Intensity Focused Ultrasound (‘HIFU’) Division and the Urological Devices and Services (‘UDS’) Division.

In January 2007, the Company announced that a fourth segment was created, named FDA PMA, to report the on the clinical activity pursuing the FDA approval for the Ablatherm.

Segment operating profit or loss are determined in accordance with the same policies as those described in the summary of significant accounting policies except that interest income and expense, current and deferred income taxes, are not allocated to individual segments. A reconciliation of segment operating profit or loss to consolidated net loss is as follows:

	6 months 2015			6 months 2014
Segment operating loss		(839	)		(1,046	)
Interest income, net		(1,344	)		(3,554	)
Foreign Currency exchange (losses) gains, net		303			216
Other income, net		(3	)		(4	)
Income tax (expense) credit net		(69	)		(36	)
Consolidated net loss net		(1,953	)		(4,425	)

A summary of the Company’s operations by business unit is presented below for periods ending June 30, 2015 and 2014:

	HIFU Division			UDS Division			EDAP TMS Corporate			FDA PMA			Total consolidated
6 months 2015
Sales of Goods (incl. consumables)		2,318			6,785			-			-			9,103
Sales of RPPs & Leases,		1,297			822			-			-			2,119
Sales of Spare Parts & Services		333			2,497									2,830
Total Net Sales		3,948			10,104			-			-			14,052
Other Revenues		2			-									2
Total Revenues		3,950			10,104			-			-			14,054
Gross Profit		2,158			3,753			-			-			5,911
Research & Development		(745	)		(455	)		-			(312	)		(1,512	)
SG&A + Depreciation		(1,504	)		(3,014	)		(721	)		-			(5,238	)
Operating income (loss)		(91	)		284			(721	)		(312	)		(839	)

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM UNAUDITED FINANCIAL STATEMENTS

(in thousands of euros unless otherwise noted, except per share data)

	HIFU Division			UDS Division			EDAP TMS Corporate			FDA PMA			Total consolidated
6 months 2014
Sales of Goods (incl. consumables)		3,252			5,504			-			-			8,756
Sales of RPPs & Leases,		1,103			920			-			-			2,023
Sales of Spare Parts & Services		433			2,185									2,618
Total Net Sales		4,789			8,608			-			-			13,397
Other Revenues		-			-									-
Total Revenues		4,789			8,608			-			-			13,397
Gross Profit		2,643			2,724			-			-			5,367
Research & Development		(614	)		(434	)		-			(570	)		(1,618	)
SG&A + Depreciation		(1,265	)		(2,811	)		(720	)		-			(4,796	)
Operating income (loss)		765			(521	)		(720	)		(570	)		(1,046	)

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Subsequent Significant Events

6 Months Ended

Jun. 30, 2015

Subsequent Significant Events [Text Block]

SUBSEQUENT SIGNIFICANT EVENTS

10.1 – Resignation of Chief Financial Officer and nomination of new CFO

On June 30, 2015, Eric Soyer officially resigned from his position as Chief Financial Officer of the Company and Managing Director of the French Operations. On July 14, 2015, François Dietsch was promoted Chief Financial Officer of EDAP TMS replacing Eric Soyer.

10.2 – FDA update

On July 21, 2015, the Company received a letter from the U.S. Food and Drug Administration (“FDA”) related to its Direct De Novo 510(k) petition for Ablatherm HIFU in the United States. The “Deficiency List” (as such communications about a regulatory filing are officially designated) identifies items and topics for which the FDA has requested additional information or further clarifications to continue its ongoing review. Only four (4) points were raised in the Deficiency List, and the FDA requested (i) the results of EDAP’s reprocessing validation tests, (ii) additional information regarding the Company’s physician training program, (iii) additions and modifications to the draft labeling materials, and (iv) additions and modifications to the draft user manual.

On August 25, 2015, the Company announced it submitted a complete, formal response to the FDA "Deficiency List". The FDA review of EDAP’s Direct De Novo 510(k) petition, which had been on hold pending submission of the response, will now resume.

10.3 – Legal proceedings update

Following the August 4, 2014 class action law suit filed against the Company (ref. “Item 8. Financial Information / Legal Proceedings” of our 20 -F Report filed with the SEC on April 2, 2015), on September 14, 2015, the defendants’ motion to dismiss the plaintiffs’ claims, filed by the defendants on February 20, 2015, was granted in its entirety by the U.S. District Court for the Southern District of New York. If the plaintiffs appeal or seek other relief from the court’s ruling, the defendants will continue to defend the matter vigorously, but cannot predict the likely outcome.

Cash and Cash Equivalents Disclosure (Tables)

6 Months Ended

Jun. 30, 2015

Schedule of Cash and Cash Equivalents [Table Text Block]

	06 - 30 - 2015		12 - 31 - 2014
Total cash and cash equivalents		10,851		11,142
Short term investments		1,000		1,000
Total cash and cash equivalent and short term investments		11,851		12,142

Inventories (Tables)

6 Months Ended

Jun. 30, 2015

Schedule of Inventory, Current [Table Text Block]

	06 - 30 - 2015			12 - 31 - 2014
Components, spare parts		3,812			4,225
Work-in-progress		1,056			832
Finished goods		2,029			1,591
Total gross inventories		6,898			6,648
Less: provision for slow-moving inventory		(874	)		(741	)
Total		6,023			5,908

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2015

Schedule of Debt [Table Text Block]

	06 - 30 - 2015			12 - 31 - 2014
Japanese yen term loan		203			234
Italy term loan		198			220
Malaysia term loan		3			5
Total long term debt		404			458
Less current portion		(117	)		(116	)
Total long-term portion		287			342

Schedule of f inancial instruments carried at fair value [Table Text Block]

	06 - 30 - 2015			12 - 31 - 2014

Investor Warrants		3,434			1,943
Placement Agent Warrants		155			148
Total		3,589			2,092
Less current portion		(67	)		-
Total long-term portion		3,523			2,092

Long Term Debt Schedule 2 [Table Text Block]

	Amount		Maturation		Interest rate
EDAP Technomed Co. Ltd		10,000,000		March 31, 2015		0.10%
		55,000,000		June 30, 2018		1.80%
		10,000,000		June 30, 2018		0.10%

Long Term Debt Schedule 3 [Table Text Block]

	Amount		Maturation		Interest rate
EDAP Technomed Co. Ltd		55,000,000		June 30, 2018		1.80%
		10,000,000		June 30, 2018		0.10%

Schedule Of Long Term Debt Maturities [Table Text Block]

2015			52
2016			272
2017			1,709
2018			1,934
2019			27
Total			3,994

Shareholders Equity (Tables)

6 Months Ended

Jun. 30, 2015

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

	June 30, 2015					December 31, 2014					December 31, 2013
	Options			Weighted average exercise price (€)		Options			Weighted average exercise price (€)		Options		Weighted average exercise price (€)
Outstanding on January 1,		1,095,850			2.76		1,310,850			2.70		810,850		3.18
Granted		-			-		-			-		500,000		1.91
Exercised		-			-		(750	)		3.99		-		-
Forfeited		(106,250	)		2.88		(90,250	)		2.07		-		-
Expired		-			-		(124,000	)		2.60		-		-
Outstanding at the end of the period		989,600			2.74		1,095,850			2.76		1,310,850		2.70
Exercisable at the end of the period		797,100			2.95		784,600			3.09		743,347		3.27
Shares purchase options available for grant on at end of period		232,428					83,428					83,428

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

	Outstanding options								Fully vested options ⁽¹⁾
Exercise price (€)	Options		Weighted average remaining contractual life		Weighted average exercise price (€)		Aggregate Intrinsic Value ⁽²⁾		Options		Weighted average exercise price (€)		Aggregate Intrinsic Value ⁽²⁾
3.99		364,588		2.3		3.99		-		364,588		3.99		-
2.38		149,100		5.0		2.38		78,224		149,100		2.38		78,224
1.91		400,000		7.5		1.91		397,855		207,500		1.91		206,387
1.88		75,912		5.5		1.88		77,782		75,912		1.88		77,782
1.88 to 3.99		989,600		5.0		2.74		553,861		797,100		2.95		362,393

Financial Income, Net (Tables)

6 Months Ended

Jun. 30, 2015

Schedule of financial income (expense) [Table Text Block]

	6 months 2015			6 months 2014
Interest income 12		3			12
Interest expense		(28	)		(32	)
Warrants exercises		66			-
Changes in fair value of the warrants		(1,385	)		(3,534	)
Total		(1,344	)		(3,554	)

Segment Information (Tables)

6 Months Ended

Jun. 30, 2015

Reconciliation of operating profit (loss) from segments to consolidated [Table] [Table Text Block]

	6 months 2015			6 months 2014
Segment operating loss		(839	)		(1,046	)
Interest income, net		(1,344	)		(3,554	)
Foreign Currency exchange (losses) gains, net		303			216
Other income, net		(3	)		(4	)
Income tax (expense) credit net		(69	)		(36	)
Consolidated net loss net		(1,953	)		(4,425	)

ScheduleOfSegment Reporting Information By Segment Bis [Table Text Block]

	HIFU Division			UDS Division			EDAP TMS Corporate			FDA PMA			Total consolidated
6 months 2015
Sales of Goods (incl. consumables)		2,318			6,785			-			-			9,103
Sales of RPPs & Leases,		1,297			822			-			-			2,119
Sales of Spare Parts & Services		333			2,497									2,830
Total Net Sales		3,948			10,104			-			-			14,052
Other Revenues		2			-									2
Total Revenues		3,950			10,104			-			-			14,054
Gross Profit		2,158			3,753			-			-			5,911
Research & Development		(745	)		(455	)		-			(312	)		(1,512	)
SG&A + Depreciation		(1,504	)		(3,014	)		(721	)		-			(5,238	)
Operating income (loss)		(91	)		284			(721	)		(312	)		(839	)

ScheduleOfSegment Reporting Information By Segment Ter [Table Text Block]

	HIFU Division			UDS Division			EDAP TMS Corporate			FDA PMA			Total consolidated
6 months 2014
Sales of Goods (incl. consumables)		3,252			5,504			-			-			8,756
Sales of RPPs & Leases,		1,103			920			-			-			2,023
Sales of Spare Parts & Services		433			2,185									2,618
Total Net Sales		4,789			8,608			-			-			13,397
Other Revenues		-			-									-
Total Revenues		4,789			8,608			-			-			13,397
Gross Profit		2,643			2,724			-			-			5,367
Research & Development		(614	)		(434	)		-			(570	)		(1,618	)
SG&A + Depreciation		(1,265	)		(2,811	)		(720	)		-			(4,796	)
Operating income (loss)		765			(521	)		(720	)		(570	)		(1,046	)

Summary Of Significant Accounting Policies (Narrative) (Details)	6 Months Ended
	Jun. 30, 2014 d yr
Summary Of Significant Accounting Policies 1	1
Summary Of Significant Accounting Policies 2	1
Summary Of Significant Accounting Policies 3	1
Summary Of Significant Accounting Policies 4	2
Summary Of Significant Accounting Policies 5	1
Summary Of Significant Accounting Policies 6	3
Summary Of Significant Accounting Policies 7	1
Summary Of Significant Accounting Policies 8	4
Summary Of Significant Accounting Policies 9	11
Summary Of Significant Accounting Policies 10	1
Summary Of Significant Accounting Policies 11	5
Summary Of Significant Accounting Policies 12	1
Summary Of Significant Accounting Policies 13	6
Summary Of Significant Accounting Policies 14 \| d	90
Summary Of Significant Accounting Policies 15 \| d	90
Summary Of Significant Accounting Policies 16	1
Summary Of Significant Accounting Policies 17	7
Summary Of Significant Accounting Policies 18	1
Summary Of Significant Accounting Policies 19	8
Summary Of Significant Accounting Policies 20	1
Summary Of Significant Accounting Policies 21	9
Summary Of Significant Accounting Policies 22	10
Summary Of Significant Accounting Policies 23	3
Summary Of Significant Accounting Policies 24	10
Summary Of Significant Accounting Policies 25	2
Summary Of Significant Accounting Policies 26	10
Summary Of Significant Accounting Policies 27	12
Summary Of Significant Accounting Policies 28	1
Summary Of Significant Accounting Policies 29	10
Summary Of Significant Accounting Policies 30	1
Summary Of Significant Accounting Policies 31	11
Summary Of Significant Accounting Policies 32	5
Summary Of Significant Accounting Policies 33	5
Summary Of Significant Accounting Policies 34	7
Summary Of Significant Accounting Policies 35	1
Summary Of Significant Accounting Policies 36	12
Summary Of Significant Accounting Policies 37	13
Summary Of Significant Accounting Policies 38	1
Summary Of Significant Accounting Policies 39	13
Summary Of Significant Accounting Policies 40	1
Summary Of Significant Accounting Policies 41	2
Summary Of Significant Accounting Policies 42	1
Summary Of Significant Accounting Policies 43	14
Summary Of Significant Accounting Policies 44	1
Summary Of Significant Accounting Policies 45	15
Summary Of Significant Accounting Policies 46	1
Summary Of Significant Accounting Policies 47	16
Summary Of Significant Accounting Policies 48	1
Summary Of Significant Accounting Policies 49	17
Summary Of Significant Accounting Policies 50	14
Summary Of Significant Accounting Policies 51	1
Summary Of Significant Accounting Policies 52	18
Summary Of Significant Accounting Policies 53	1
Summary Of Significant Accounting Policies 54	19
Summary Of Significant Accounting Policies 55	1
Summary Of Significant Accounting Policies 56	20
Summary Of Significant Accounting Policies 57	6
Summary Of Significant Accounting Policies 58	1
Summary Of Significant Accounting Policies 59	21
Summary Of Significant Accounting Policies 60	15
Summary Of Significant Accounting Policies 61	1
Summary Of Significant Accounting Policies 62	22
Summary Of Significant Accounting Policies 63	0
Summary Of Significant Accounting Policies 64	0
Summary Of Significant Accounting Policies 65	0
Summary Of Significant Accounting Policies 66	75.00%
Summary Of Significant Accounting Policies 67	0
Summary Of Significant Accounting Policies 68	90.00%

Goodwill And Intangible Assets (Narrative) (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Goodwill	€ 2,412	€ 2,412

Lease Obligations (Narrative) (Details) - Equipment Held under Capital Leases [Member] € in Thousands	Jun. 30, 2015 EUR (€)
medical devices	€ 209
vehicles	€ 291

Short-Term Borrowings (Narrative) (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Jun. 30, 2014
account receivables factored	€ 1,980	€ 972
loan in euro	€ 1,000	€ 1,000

Shareholders Equity (Narrative) (Details) - € / shares	1 Months Ended		2 Months Ended	5 Months Ended		6 Months Ended	12 Months Ended
Shareholders Equity (Narrative) (Details) - € / shares	Jan. 18, 2013	Jun. 25, 2010	Jul. 31, 2001	Oct. 29, 2007	Dec. 31, 1998	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 19, 2012	Jun. 24, 2010	May 22, 2007
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						0	0	500,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Exercise Price						€ 0	€ 0	€ 1.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						989,600	1,095,850	1,310,850	810,850
Treasury Stock, Shares, Acquired			49,540		331,988
Plan 2 - 2007 [Member] \| Employee Stock Option [Member] \| Common Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized												600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		95,912		504,088
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						440,500
Plan 3 - 2010 [Member] \| Employee Stock Option [Member] \| Common Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized											229,100
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		229,100
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						149,100
Plan 4 - 2012 [Member] \| Employee Stock Option [Member] \| Common Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						400,000

Other Revenues (Narrative) (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Other Revenue, Net	€ 2	€ 0

Schedule of Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Cash and cash equivalents	€ 10,851	€ 11,142	€ 6,804	€ 6,681
Short-term investment	1,000	1,000
Total cash and cash equivalents, and short term investments	€ 11,851	€ 12,142

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References + Details

Schedule of Accounts, Notes, Loans and Financing Receivable (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current portion of net trade accounts and notes receivable	€ 9,121	€ 6,943
Total long-term portion	€ 553	€ 638

Schedule of other receivables (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
NontradeReceivablesCurrent	€ 1,037	€ 1,200

Schedule of Inventory, Current (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Components, spare parts	€ 3,812	€ 4,225
Work-in-progress	1,056	832
Finished goods	2,029	1,591
Total gross inventories	6,898	6,648
Less: provision for slow-moving inventory	(874)	(741)
Total	€ 6,023	€ 5,908

Schedule of Other Assets (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Total	€ 377	€ 381

Schedule of Property, Plant and Equipment (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Total	€ 2,116	€ 2,122

Schedule of Accounts Payable and Accrued Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Total	€ 4,977	€ 5,505

Schedule of Future Minimum Lease Payments for Capital Leases (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current portion of capital lease obligations	€ 213	€ 217
Long-term portion	€ 287	€ 355

Schedule of Debt (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Total long term debt	€ 404	€ 458
Less current portion	117	116
Total long-term portion	287	342
JAPAN [Member]
Total long term debt	203	234
ITALY [Member]
Total long term debt	198	220
MALAYSIA [Member]
Total long term debt	€ 3	€ 5

Schedule of f inancial instruments carried at fair value (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Less current portion	€ 67	€ 0
Total long-term portion	3,523	2,092
Total Financial Instruments [Member]
Total Financial Instruments	3,589	2,092
Placement Agent Warrants [Member]
Total Financial Instruments	155	148
Investor warrants [Member]
Total Financial Instruments	€ 3,434	€ 1,943

Schedule of details of debts (Details) - JAPAN [Member] - Edap Technomed Co Ltd [Member] - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Loan One [Member]
Initial Amount		€ 10,000,000
Interest rate		0.10
Loan Two [Member]
Initial Amount	€ 55,000,000	55,000,000
Interest rate	1.80	1.80
Loan Three [Member]
Initial Amount	10,000,000	10,000,000
Interest rate	€ 0.10	€ 0.10

Schedule Of Long-term Debt, Debentures And Financial InstrumentsMaturities (Details)	Jun. 30, 2014 EUR (€)
2015	€ 52
2016	272
2017	1,709
2018	1,934
2019	€ 27

Long Term Debt Schedule 2 (Details) - JAPAN [Member] - Edap Technomed Co Ltd [Member] - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Loan One [Member]
Initial Amount		€ 10,000,000
Interest rate		0.10
Loan Two [Member]
Initial Amount	€ 55,000,000	55,000,000
Interest rate	1.80	1.80
Loan Three [Member]
Initial Amount	10,000,000	10,000,000
Interest rate	€ 0.10	€ 0.10

Long Term Debt Schedule 3 (Details) - JAPAN [Member] - Edap Technomed Co Ltd [Member] - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Loan One [Member]
Initial Amount		€ 10,000,000
Interest rate		0.10
Loan Two [Member]
Initial Amount	€ 55,000,000	55,000,000
Interest rate	1.80	1.80
Loan Three [Member]
Initial Amount	10,000,000	10,000,000
Interest rate	€ 0.10	€ 0.10

Schedule of other long term liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014
Total	€ 2,254	€ 1,991

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) - € / shares	1 Months Ended		5 Months Ended	6 Months Ended	12 Months Ended
	Jan. 18, 2013	Jun. 25, 2010	Oct. 29, 2007	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Granted - Number				0	0	500,000
Exercised - Number				0	(750)	0
Forfeited - Number				(106,250)	(90,250)	0
Expired - Number				0	(124,000)
Outstanding - Number				989,600	1,095,850	1,310,850	810,850
Exercisable - Number				797,100	784,600	743,347
Share purchase options available for grant - Number				232,428	83,428	83,428
Outstanding - Weighted average exercise price				€ 2.74	€ 2.76	€ 2.70	€ 3.18
Granted - Weighted average exercise price				0	0	1.91
Exercized - Weighted average exercise price				0	3.99	0
Forfeited - Weighted average exercise price				2.88	2.07	0
Expired - Weighted average exercise price				0	2.60	0
Exercisable - Weighted average exercise price				€ 2.95	€ 3.09	€ 3.27
Plan 2 - 2007 [Member] \| Employee Stock Option [Member] \| Common Class A [Member]
Granted - Number		95,912	504,088
Outstanding - Number				440,500
Plan 3 - 2010 [Member] \| Employee Stock Option [Member] \| Common Class A [Member]
Granted - Number		229,100
Outstanding - Number				149,100
Plan 4 - 2012 [Member] \| Employee Stock Option [Member] \| Common Class A [Member]
Granted - Number	500,000
Outstanding - Number				400,000

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (Details)	6 Months Ended
	Jun. 30, 2014 EUR (€) € / shares shares
1.88 [Member]
Outstanding options - Number \| shares	75,912
Outstanding options - Weighted average remaining contractual life	5 years 6 months
Outstanding options - Weighted average exercise price \| € / shares	€ 1.88
Outstanding options - Intrinsic value \| €	€ 77,782
Exercisable options - Number \| shares	75,912
Exercisable options - Weighted average exercise price \| € / shares	€ 1.88
Exercisable options - Intrinsic value \| €	€ 77,782
2.38 [Member]
Outstanding options - Number \| shares	149,100
Outstanding options - Weighted average remaining contractual life	5 years
Outstanding options - Weighted average exercise price \| € / shares	€ 2.38
Outstanding options - Intrinsic value \| €	€ 78,224
Exercisable options - Number \| shares	149,100
Exercisable options - Weighted average exercise price \| € / shares	€ 2.38
Exercisable options - Intrinsic value \| €	€ 78,224
3.99 [Member]
Outstanding options - Number \| shares	364,588
Outstanding options - Weighted average remaining contractual life	2 years 3 months 18 days
Outstanding options - Weighted average exercise price \| € / shares	€ 3.99
Outstanding options - Intrinsic value \| €	€ 0
Exercisable options - Number \| shares	364,588
Exercisable options - Weighted average exercise price \| € / shares	€ 3.99
Exercisable options - Intrinsic value \| €	€ 0
1.91 [Member]
Outstanding options - Number \| shares	400,000
Outstanding options - Weighted average remaining contractual life	7 years 6 months
Outstanding options - Weighted average exercise price \| € / shares	€ 1.91
Outstanding options - Intrinsic value \| €	€ 397,855
Exercisable options - Number \| shares	207,500
Exercisable options - Weighted average exercise price \| € / shares	€ 1.91
Exercisable options - Intrinsic value \| €	€ 206,387
1.88 to 3.99 [Member]
Outstanding options - Number \| shares	989,600
Outstanding options - Weighted average remaining contractual life	5 years
Outstanding options - Weighted average exercise price \| € / shares	€ 2.74
Outstanding options - Intrinsic value \| €	€ 553,861
Exercisable options - Number \| shares	797,100
Exercisable options - Weighted average exercise price \| € / shares	€ 2.95
Exercisable options - Intrinsic value \| €	€ 362,393

Changes In Warrants Stock Options And Capital Increase (Details) € in Thousands	6 Months Ended
	Jun. 30, 2015 EUR (€)
Warrants and stock options granted	€ 27
Capital increase	€ 208

Schedule of other revenues (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Other Revenue, Net	€ 2	€ 0

Schedule of Research and development expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Research and Development Expense	€ 1,512	€ 1,618

Schedule of financial income (expense) (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Interest income	€ 3	€ 12
Interest expense	(28)	(32)
Warrants exercises	66	0
Changes in fair value of the warrants	(1,385)	(3,534)
Financial (expense) income, net	€ (1,344)	€ (3,554)

Schedule of Components of Income Tax Expense (Benefit) (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Deferred Income Tax (Expense) Benefit	€ 22	€ (9)
Income tax (expense) benefit	€ (69)	€ (36)

Schedule of Earnings Per Share, Basic and Diluted (Details) - € / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Weighted Average Number of Shares Outstanding, Diluted	24,926,627	22,273,003
Basic net earnings (loss) per share	€ (0.08)	€ (0.20)
Diluted net earnings (loss) per share (1)	€ (0.08)	€ (0.20)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

Schedule of Fair Value Measurement Inputs Level 1 (Details) - EUR (€) € in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Assets [Abstract]
Cash and cash equivalents	€ 10,851	€ 11,142	€ 6,804	€ 6,681
Short-term investment	1,000	1,000
Liabilities [Abstract]
Short-term borrowings	2,982	2,126
Long-term Debt	€ 404	€ 458

Reconciliation of operating profit (loss) from segments to consolidated [Table] (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Segment operating loss	€ (839)	€ (1,046)
Financial income (expense), net	(1,344)	(3,554)
Foreign currency exchange gain (loss), net	303	216
FinancialExpenseIncomeNet	(1,344)	(3,554)
Other income (expense), net	(3)	(4)
Income tax (expense) benefit	(69)	(36)
Net income (loss)	€ (1,953)	€ (4,425)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

ScheduleOfSegment Reporting Information By Segment Bis (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Sales of goods	€ 9,103	€ 8,756
Sales of RPPs and leases	2,119	2,023
Sales of spare parts and services	2,830	2,618
Total sales	14,052	13,397
Total net sales		13,397
Other Revenue, Net	2	0
Total revenues	14,054	13,397
Total cost of sales	(8,143)	(8,030)
Gross profit	5,911	5,367
Research and development expenses	(1,512)	(1,618)
Selling and marketing expenses	(3,408)	(3,064)
General and administrative expenses	(1,830)	(1,732)
Loss from operations	(839)	(1,046)
Total assets	33,901		€ 32,154
Goodwill	2,412		€ 2,412
Urology Devices and Services (UDS) [Member]
Sales of goods	6,785	5,504
Sales of RPPs and leases	822	920
Sales of spare parts and services	2,497	2,185
Total net sales	10,104	8,608
Other Revenue, Net	0	0
Total revenues	10,104	8,608
Gross profit	3,753	2,724
Research and development expenses	(455)	(434)
General and administrative expenses	(3,014)	(2,811)
Loss from operations	284	(521)
FDA [Member]
Sales of goods	0	0
Sales of RPPs and leases	0	0
Total net sales	0	0
Other Revenue, Net		0
Total revenues	0
Gross profit	0	0
Research and development expenses	(312)	(570)
General and administrative expenses	0	0
Loss from operations	(312)	(570)
EDAP TMS (Corporate) [Member]
Sales of goods	0	0
Sales of RPPs and leases	0	0
Total net sales	0	0
Total revenues	0	0
Gross profit	0	0
Research and development expenses	0	0
General and administrative expenses	(721)	(720)
Loss from operations	(721)	(720)
High Intensity Focused Ultrasound (HIFU) [Member]
Sales of goods	2,318	3,252
Sales of RPPs and leases	1,297	1,103
Sales of spare parts and services	333	433
Total net sales	3,948	4,789
Other Revenue, Net	2	0
Total revenues	3,950	4,789
Gross profit	2,158	2,643
Research and development expenses	(745)	(614)
General and administrative expenses	(1,504)	(1,265)
Loss from operations	€ (91)	€ 765

ScheduleOfSegment Reporting Information By Segment Ter (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Sales of goods	€ 9,103	€ 8,756
Sales of RPPs and leases	2,119	2,023
Sales of spare parts and services	2,830	2,618
Total sales	14,052	13,397
Total net sales		13,397
Other Revenue, Net	2	0
Total revenues	14,054	13,397
Total cost of sales	8,143	8,030
Gross profit	5,911	5,367
Research and development expenses	(1,512)	(1,618)
Selling and marketing expenses	(3,408)	(3,064)
General and administrative expenses	(1,830)	(1,732)
Loss from operations	(839)	(1,046)
Total assets	33,901		€ 32,154
Goodwill	2,412		€ 2,412
Urology Devices and Services (UDS) [Member]
Sales of goods	6,785	5,504
Sales of RPPs and leases	822	920
Sales of spare parts and services	2,497	2,185
Total net sales	10,104	8,608
Other Revenue, Net	0	0
Total revenues	10,104	8,608
Gross profit	3,753	2,724
Research and development expenses	(455)	(434)
General and administrative expenses	(3,014)	(2,811)
Loss from operations	284	(521)
FDA [Member]
Sales of goods	0	0
Sales of RPPs and leases	0	0
Total net sales	0	0
Other Revenue, Net		0
Total revenues	0
Gross profit	0	0
Research and development expenses	(312)	(570)
General and administrative expenses	0	0
Loss from operations	(312)	(570)
EDAP TMS (Corporate) [Member]
Sales of goods	0	0
Sales of RPPs and leases	0	0
Total net sales	0	0
Total revenues	0	0
Gross profit	0	0
Research and development expenses	0	0
General and administrative expenses	(721)	(720)
Loss from operations	(721)	(720)
High Intensity Focused Ultrasound (HIFU) [Member]
Sales of goods	2,318	3,252
Sales of RPPs and leases	1,297	1,103
Sales of spare parts and services	333	433
Total net sales	3,948	4,789
Other Revenue, Net	2	0
Total revenues	3,950	4,789
Gross profit	2,158	2,643
Research and development expenses	(745)	(614)
General and administrative expenses	(1,504)	(1,265)
Loss from operations	€ (91)	€ 765

Schedule Of Segment Reporting Information By Segment Quarter (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Sales of goods	€ 9,103	€ 8,756
Sales of RPPs and leases	2,119	2,023
Sales of spare parts and services	2,830	2,618
Total sales	14,052	13,397
Total net sales		13,397
Other Revenue, Net	2	0
Total revenues	14,054	13,397
Total cost of sales	8,143	8,030
Gross profit	5,911	5,367
Research and development expenses	1,512	1,618
Selling and marketing expenses	3,408	3,064
General and administrative expenses	1,830	1,732
Loss from operations	(839)	(1,046)
Total assets	33,901		€ 32,154
Goodwill	2,412		€ 2,412
Urology Devices and Services (UDS) [Member]
Sales of goods	6,785	5,504
Sales of RPPs and leases	822	920
Sales of spare parts and services	2,497	2,185
Total net sales	10,104	8,608
Other Revenue, Net	0	0
Total revenues	10,104	8,608
Gross profit	3,753	2,724
Research and development expenses	455	434
General and administrative expenses	3,014	2,811
Loss from operations	284	(521)
FDA [Member]
Sales of goods	0	0
Sales of RPPs and leases	0	0
Total net sales	0	0
Other Revenue, Net		0
Total revenues	0
Gross profit	0	0
Research and development expenses	312	570
General and administrative expenses	0	0
Loss from operations	(312)	(570)
EDAP TMS (Corporate) [Member]
Sales of goods	0	0
Sales of RPPs and leases	0	0
Total net sales	0	0
Total revenues	0	0
Gross profit	0	0
Research and development expenses	0	0
General and administrative expenses	721	720
Loss from operations	(721)	(720)
High Intensity Focused Ultrasound (HIFU) [Member]
Sales of goods	2,318	3,252
Sales of RPPs and leases	1,297	1,103
Sales of spare parts and services	333	433
Total net sales	3,948	4,789
Other Revenue, Net	2	0
Total revenues	3,950	4,789
Gross profit	2,158	2,643
Research and development expenses	745	614
General and administrative expenses	1,504	1,265
Loss from operations	€ (91)	€ 765